Published in Toxicol Pathol on January 06, 1997
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res (2008) 2.00
Measuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP. Mol Imaging Biol (2011) 1.50
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2008) 1.29
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate (2013) 1.15
Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog (2007) 1.14
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07
Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res (2008) 1.02
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl (2008) 0.90
Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study. Cancer Res (2009) 0.89
Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis (2012) 0.85
Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression. ISRN Oncol (2013) 0.84
Growth and Progression of TRAMP Prostate Tumors in Relationship to Diet and Obesity. Prostate Cancer (2012) 0.82
Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Lab Anim Res (2014) 0.79
Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate. Proc Natl Acad Sci U S A (2016) 0.78
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother (2016) 0.76
Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse. Comp Med (2013) 0.76
Effects of dietary high fat on prostate intraepithelial neoplasia in TRAMP mice. Lab Anim Res (2013) 0.76
(Z)-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane induces concentration-dependent growth inhibition, apoptosis, and coordinates regulation of apoptotic genes in TRAMP cells. Urol Oncol (2007) 0.75
Laboratory animal pathology--emphasis on an area of relevance to the toxicologic pathologist. Toxicol Pathol (1997) 0.75
Kinetics of marked development of lung metastasis of rat prostatic carcinomas transplanted in syngeneic rats. Clin Exp Metastasis (2005) 0.75
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res (1997) 3.67
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis (1999) 2.37
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology (1996) 1.74
Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res (2001) 1.66
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res (2001) 1.59
The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol (2001) 1.57
The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res (1999) 1.42
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol (2001) 1.35
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res (2000) 1.31
A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res (1999) 1.25
Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res (2000) 1.24
Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res (2001) 1.17
Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol (2001) 1.16
Structure and transcription analysis of the gene encoding a cellobiase from Agrobacterium sp. strain ATCC 21400. J Bacteriol (1988) 1.15
Regulation, initiation, and termination of the cenA and cex transcripts of Cellulomonas fimi. J Bacteriol (1987) 1.14
Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene (2007) 1.13
Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer. Prostate (2001) 1.13
Early castration reduces prostatic carcinogenesis in transgenic mice. Urology (1999) 1.07
Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem (2000) 1.07
Prostate specific expression of Cre recombinase in transgenic mice. Genesis (2000) 1.04
Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol (1998) 1.00
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene (1999) 0.97
Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis (2003) 0.94
Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev (1999) 0.92
Tyrosine kinase inhibitor AG18 arrests follicle-stimulating hormone-induced granulosa cell differentiation: use of reverse transcriptase-polymerase chain reaction assay for multiple messenger ribonucleic acids. Endocrinology (1994) 0.91
Genomic instability-based transgenic models of prostate cancer. Carcinogenesis (2000) 0.90
Centrosome-centriole abnormalities are markers for abnormal cell divisions and cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) model. Biol Cell (2000) 0.90
Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate (1998) 0.89
Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis (1999) 0.88
Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene (2007) 0.86
Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model. J Urol (1999) 0.85
Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis (2003) 0.84
Transgenic models for prostate cancer research. Urol Oncol (2011) 0.82
Recent advances in the development of animal and cell culture models for prostate cancer research A minireview. Urol Oncol (2011) 0.79
Production of human surfactant protein C in milk of transgenic mice. Transgenic Res (1995) 0.79
Secretion of unprocessed human surfactant protein B in milk of transgenic mice. Transgenic Res (1997) 0.75
Casein gene expression: from transfection to transgenics. Cancer Treat Res (1992) 0.75